Cargando…
Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
BACKGROUND: The effectiveness of ustekinumab (UST) in the treatment of Crohn’s disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world effectiven...
Autores principales: | Parra, Rogério Serafim, Chebli, Júlio Maria Fonseca, Queiroz, Natália Sousa Freitas, Damião, Aderson Omar Mourão Cintra, de Azevedo, Matheus Freitas Cardoso, Chebli, Liliana Andrade, Bertges, Erika Ruback, Alves Junior, Antonio José Tiburcio, Ambrogini Junior, Orlando, da Silva, Bianca Loyo Pona Schiavetti, Lubini, Marcio, Bafutto, Mauro, Flores, Cristina, Vilela, Eduardo Garcia, Boratto, Sandra Felice, Gasparetti Junior, Newton Luiz Tricarico, Steinwurz, Flavio, Carvalho, Nayara Salgado, Féres, Omar, da Rocha, José Joaquim Ribeiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027080/ https://www.ncbi.nlm.nih.gov/pubmed/35448949 http://dx.doi.org/10.1186/s12876-022-02280-3 |
Ejemplares similares
-
How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2021) -
A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014) -
Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study
por: Parra, Rogério Serafim, et al.
Publicado: (2023) -
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
por: Garcia, Karoline Soares, et al.
Publicado: (2023) -
Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil
por: Chebli, Julio Maria Fonseca, et al.
Publicado: (2022)